ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

ESHAP is an active regimen for relapsing Hodgkin's disease (1999)

Aparicio, J. ; Segura, A. ; Garcerá, S. ; [et al.]

Springer

Annals of oncology 10 (1999), S. 593-595

add to mindlist on the mindlist

Details

ISSN: 1569-8041

Keywords: Hodgkin's disease ; relapse ; salvage chemotherapy

Source: Springer Online Journal Archives 1860-2000

Topics: Medicine

Notes: Abstract Background: Refractory or relapsing Hodgkin's disease is associated with a poor prognosis. There is no widely accepted salvage chemotherapy regimen for these patients. However, the addition of high-dose chemotherapy followed by autologous hematopoietic transplantation (AHT) has proven of benefit to them. A prospective clinical trial was carried out to evaluate the efficacy and toxicity of ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin). Patients and methods: Twenty-two patients with refractory (5) or relapsing Hodgkin's disease (17) were entered and scheduled to receive three courses of ESHAP. Patients suitable for AHT were then given high-dose chemotherapy with CBV (cyclophosphamide, carmustine, and etoposide) plus AHT, whereas responding, non-AHT-suitable patients completed six ESHAP courses. Results: Nine patients achieved complete responses and seven partial responses (overall response rate 73%) with ESHAP. Grade 3–4 myelotoxicity was seen in 13 patients (59%). Nine patients received CBV plus AHT. At a median follow-up time of 50 months (range 6–96), seven patients (32%) are alive and disease-free. Three patients died of toxic effects of ESHAP (1) or CBV (2). Actuarial overall survival and disease-free survival were 35% and 27% at three years. Conclusions: ESHAP is an active regimen for relapsing Hodgkin's disease, with myelosuppression as its dose-limiting toxicity. An increased risk of treatment-related mortality when it is combined with high-dose chemotherapy can not be ruled out.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1023/A:1026454831340

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Influence of the catalyst on the kinetics of a RIM formulation (1989)

Rego, J. M. ; Pastor, M. A. ; Campo, J. J. ; [et al.]

New York, NY [u.a.] : Wiley-Blackwell

Journal of Applied Polymer Science 38 (1989), S. 237-248

add to mindlist on the mindlist

Details

ISSN: 0021-8995

Keywords: Chemistry ; Polymer and Materials Science

Source: Wiley InterScience Backfile Collection 1832-2000

Topics: Chemistry and Pharmacology , Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision Mechanics , Physics

Notes: The influence of three different catalysts [triethylendiamine (TD), stannous octoate (SO), and dibutylindilaurate (DBTDL)] and their blends (TD + SO and TD + DBTDL) on the kinetics of a RIM formulation, based on a high functionality polyether-polyol and a polymeric MDI, has been studied using the adiabatic temperature rise method and Fourier transform infrared spectroscopy. The synergism observed in the DBTDL/TD systems is explained by means of complex formation between the amine-based and metal-based catalysts. Infrared spectroscopy data support this complex formation. The SO/TD systems do not exhibit synergetic behaviour, being the reaction rate controlled by the metal catalyst which complexes the isocyanate group.

Additional Material: 9 Ill.